Novo Nordisk gains expanded approval for Wegovy to treat heart failure
Wegovy, the blockbuster weight loss drug from Danish drugmaker Novo Nordisk has now received expanded approval from the US FDA for use in the prevention of stroke and heart attacks.
The drug can be used in overweight and obese patients to lower the risk of major adverse cardiovascular events. It currently also carries approvals to be used in obese patients with diabetes as a weight loss aid, but in this instance the prescription medication can be used in people without diabetes.
Wegovy is a semaglutide, as is Novo Nordisk’s other weight loss drug Ozempic, which belong to the GLP-1 agonist drug class. Both medications were developed for the treatment of Type 2 diabetes, working to reduce food cravings and slow the emptying of the stomach.
Patients who suffer from obesity or are overweight are at "a higher risk of cardiovascular death, heart attack and stroke. Providing a treatment option that is proven to lower this cardiovascular risk is a major advance for public health," commented John Sharretts, FDA's Director of the Division of Diabetes, Lipid Disorders, and Obesity.
The weightloss drug from Novo Nordisk are already in use by millions of patients, now in several different countries, and Wegovy has also recently been approved for use in children aged 12–18 years. The new indication for the drug means that it will be accessible to many more patients.
The rapid escalation in the prescription of the drug has led to some public concerns arising around the potential for abuse as a weight loss aid, this however is dismissed by experts saying that prescriptions are carried out by experienced practitioners. Efforts are also increasing to manage doses and monitor therapy, with Chad Weldy, a cardiologist at Stanford University, stating that he typically deferred to the primary care team to initiate and monitor therapy with drugs like Wegovy previously, but that he hopes to this change going into the future.
"Cardiology groups will need to fully incorporate these therapies into clinic and build a clinical workflow to manage dose escalation, side effects, and insurance approval," Weldy asserted.
The US FDA have noted that patients administered with Wegovy should be monitored for kidney disease, diabetic retinopathy and depression or suicidal behaviours or thoughts by a medical professional.
Novo Nordisk conducted a 33 month-long clinical trial – SELECT – involving 17,605 patients, where the drug was shown to decrease the risk of non-fatal heart attack by 28%, non-fatal stroke by 7%, and heart-related death by 15% in patients with pre-existing heart conditions, when compared with a placebo. The cardioprotective effects were seen very early on in the study, suggesting that these results were not solely due to subsequent weightloss.
The expanded approval for Wegovy could encourage higher purchasing of the drug despite its high cost (currently at US$1,349 for a month’s supply of doses).
Obesity experts in the US have also highlighted the potential of Eli Lilly’s weightloss drug, Zepbound, as a treatment for heart conditions, with the therapy undergoing tests in late-stage trials for treatment of heart failure later on in 2024.
Source:
Reuters. FDA approves Novo Nordisk's Wegovy for lowering heart risks. [Date accessed 11/03/2024] www.reuters.com/business/healthcare-pharmaceuticals/fda-approves-novo-nordisks-wegovy-use-reducing-heart-attack-risks-2024-03-08/
Related News
-
News How to disrupt an industry as big as pharma for the better?
In this interview, hear from Matthew Wise, Head of Data at CCD Partners, on the companies they've been looking into that are offering new and interesting perspectives that have the potential to shake up the pharmaceutical industry, and how they'... -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa. -
News Latest updates for semaglutide: reduction of renal failure risk
Recent data presented at the 2024 European Society for Cardiology (ESC) conference analysed Novo Nordisk’s Ozempic (semaglutide) and its effectiveness in the management of chronic kidney disease (CKD). This follows previous analysis on semaglutid... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance